Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study

Trial Profile

Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Anti-GATA3 gene-therapy (Primary)
  • Indications Asthma
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors sterna biologicals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2017 Results a pre-specified subgroup analysis from this trial were published in the Journal of Allergy and Clinical Immunology 2017, as reported in a Sterna Biologicals Media Release.
    • 07 Apr 2017 Results a pre-specified subgroup analysis published in the Sterna Biologicals Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top